本轮融资将帮助新合生物加快推进GMP车间建设，完善肿瘤新抗原真实世界数据累计及扩大肿瘤免疫治疗临床方案探索，为全球RNA制药产业链的技术突破和肿瘤免疫治疗的临床推广贡献力量。

该室间质评计划旨在评价我国高通量测序检测实验室在肿瘤体细胞突变方面的生物信息学分析能力，具有重要的意义。

未来，新合生物将充分发挥专业技术优势，为肿瘤临床检测及治疗贡献力量。

The endosomal escape of lipid nanoparticles (LNPs) is crucial for efficient mRNA-based therapeutics. Here, we present a cationic polymeric micelle (cPM) as a safe and potent co-delivery system with enhanced endosomal escape capabilities. Methods: We synthesized a cationic and ampholytic di-block copolymer, poly (poly (ethylene glycol)4-5 methacrylatea-co-hexyl methacrylateb)X-b-poly(butyl methacrylatec-co-dimethylaminoethyl methacrylated-co-propyl acrylatee)Y (p(PEG4-5MAa-co-HMAb)X-b-p(BMAc-co-DMAEMAd-co-PAAe)Y), via reversible addition–fragmentation chain transfer polymerization.

新合生物期待通过本项临床试验，进一步观察并确认基于肿瘤新抗原疫苗在治疗中晚期胃癌、食管癌的治疗效果，帮助受试者延长病情稳定性及生存期、提升生活质量。